MA42999B1 - Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë - Google Patents

Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë

Info

Publication number
MA42999B1
MA42999B1 MA42999A MA42999A MA42999B1 MA 42999 B1 MA42999 B1 MA 42999B1 MA 42999 A MA42999 A MA 42999A MA 42999 A MA42999 A MA 42999A MA 42999 B1 MA42999 B1 MA 42999B1
Authority
MA
Morocco
Prior art keywords
ivosidenib
idarubicin
cytarabine
daunorubicin
treatment
Prior art date
Application number
MA42999A
Other languages
English (en)
Other versions
MA42999A (fr
Inventor
Samuel V. AGRESTA
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of MA42999A publication Critical patent/MA42999A/fr
Publication of MA42999B1 publication Critical patent/MA42999B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour traiter des cancers chez des patients porteurs d'une mutation IDH1 à l'aide d'une combinaison d'un inhibiteur d'une enzyme IDH1 mutante et d'une thérapie d'induction et de consolidation d'une LAM.
MA42999A 2015-10-15 2016-10-14 Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë MA42999B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562242267P 2015-10-15 2015-10-15
US201562255253P 2015-11-13 2015-11-13
PCT/US2016/057036 WO2017066566A1 (fr) 2015-10-15 2016-10-14 Polythérapie pour le traitement de malignités
EP16856274.2A EP3362065B1 (fr) 2015-10-15 2016-10-14 Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë

Publications (2)

Publication Number Publication Date
MA42999A MA42999A (fr) 2018-08-22
MA42999B1 true MA42999B1 (fr) 2024-06-28

Family

ID=58518371

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42999A MA42999B1 (fr) 2015-10-15 2016-10-14 Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
MA71411A MA71411A (fr) 2015-10-15 2016-10-14 Polythérapie pour le traitement de tumeurs malignes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA71411A MA71411A (fr) 2015-10-15 2016-10-14 Polythérapie pour le traitement de tumeurs malignes

Country Status (27)

Country Link
US (1) US11419859B2 (fr)
EP (2) EP4403173A3 (fr)
JP (2) JP6871920B2 (fr)
KR (2) KR20250126877A (fr)
CN (2) CN121513029A (fr)
AU (1) AU2016338552B2 (fr)
BR (1) BR112018007671B1 (fr)
CA (2) CA3216701A1 (fr)
DK (1) DK3362065T3 (fr)
ES (1) ES2981538T3 (fr)
FI (1) FI3362065T3 (fr)
HR (1) HRP20240817T1 (fr)
HU (1) HUE067449T2 (fr)
IL (1) IL258684B2 (fr)
LT (1) LT3362065T (fr)
MA (2) MA42999B1 (fr)
MD (1) MD3362065T2 (fr)
MX (1) MX390531B (fr)
PL (1) PL3362065T3 (fr)
PT (1) PT3362065T (fr)
RS (1) RS65668B1 (fr)
SG (2) SG11201803088PA (fr)
SI (1) SI3362065T1 (fr)
SM (1) SMT202400238T1 (fr)
UA (1) UA123401C2 (fr)
WO (1) WO2017066566A1 (fr)
ZA (1) ZA201803162B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
SG11201803088PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
WO2017087885A1 (fr) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Méthodes d'identification de composés qui interfèrent avec les erreurs de routage des complexes baf liées à erg dans les cancers de la prostates liés à tmprss2-erg
TW202440123A (zh) 2017-06-12 2024-10-16 法商施維雅藥廠 以組合療法治療腦瘤之方法
TWI821189B (zh) 2017-06-12 2023-11-11 法商施維雅藥廠 使用組合療法治療腦腫瘤之方法
WO2019152437A1 (fr) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Composés et leurs utilisations
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092915A1 (fr) * 2018-11-02 2020-05-07 Celgene Corporation Dispersions solides pour le traitement du cancer
WO2020160100A1 (fr) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Composés et leurs utilisations
CA3167275A1 (fr) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Composes et leurs utilisations
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024509268A (ja) 2021-03-09 2024-02-29 フォグホーン セラピューティクス インコーポレイテッド 結晶形、それらを含有する組成物、及びそれらの使用方法
WO2024216136A1 (fr) * 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Polythérapie destinée au traitement de cancers hématologiques

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
NL125676C (fr) 1963-02-15
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
BE793501A (fr) 1971-12-31 1973-06-29 Ciba Geigy Composes heterocycliques et produits phytopharmaceutiques qui en contiennent
CH606334A5 (fr) 1974-06-21 1978-10-31 Ciba Geigy Ag
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
ES2058630T3 (es) 1989-03-03 1994-11-01 Dainippon Pharmaceutical Co Derivados de 2-(1-piperazinil)-4-fenilcicloalcanopiridinas, procedimientos de preparacion y composiciones farmaceuticas que los contienen.
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
JPH05140126A (ja) 1991-11-26 1993-06-08 Hokko Chem Ind Co Ltd トリアゾール誘導体および除草剤
CA2131004A1 (fr) 1992-02-28 1993-09-02 Hideshi Kobayashi Derive s-triazine et remede contre les maladies oestrogeno-dependantes renfermant ce derive
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
WO1998021191A1 (fr) 1995-05-16 1998-05-22 Nissan Chemical Industries, Ltd. Derives de cyanoethylmelamine et procede de production
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0912519A1 (fr) 1996-05-20 1999-05-06 Darwin Discovery Limited Sulfonamides de quinoline en tant qu'inhibiteurs de tnf et inhibiteurs de photodiesterase-iv
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
JP3887769B2 (ja) 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害
AU9064598A (en) 1998-07-10 2000-02-01 Harald Groger Precusors for pna-monomers
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
WO2000075129A1 (fr) 1999-06-07 2000-12-14 Shire Biochem Inc. Inhibiteurs d'integrine thiophene
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
CA2394727A1 (fr) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Composes de pyrimidine et de triazine presentant une activite inhibant la kinase
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
JP2004525071A (ja) 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
JP4113323B2 (ja) 2000-08-07 2008-07-09 富士フイルム株式会社 アゾ色素及びそれを含むインクジェット記録用インク、並びにインクジェット記録方法
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
WO2002088101A2 (fr) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
IL158590A0 (en) 2001-06-11 2004-05-12 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
DE60238066D1 (de) 2001-08-17 2010-12-02 Basf Se Triazinderivate und deren verwendung als sonnenschutzmittel
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
EP1546121B1 (fr) 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Inhibiteurs des kinases a base de triazine substituee
JP2004083610A (ja) 2002-08-22 2004-03-18 Fuji Photo Film Co Ltd インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
EP1575580A4 (fr) 2002-12-02 2009-06-10 Arqule Inc Methodes de traitement de cancers
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
MXPA05007382A (es) 2003-01-10 2005-11-23 Threshold Pharmaceuticals Inc Tratamiento de cancer con 2-desoxiglucosa.
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004073619A2 (fr) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Antagonistes du recepteur ccr8
WO2004074438A2 (fr) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Antagonistes de ccr8
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
WO2005013982A1 (fr) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Composes d'aminotriazole utiles en tant qu'inhibiteurs des proteines kinases
EP1689722A2 (fr) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation Derives de pyrimidine dans le traitement de troubles hyperproliferatifs
WO2005060956A1 (fr) 2003-12-12 2005-07-07 University Of Maryland, Baltimore Composes immunomodulateurs de ciblage et d'inhibition du site de liaison py+3 du domaine sh2 de la proteine p56 tyrosine kinase
CN1921864A (zh) 2003-12-24 2007-02-28 西奥斯公司 使用TGF－β抑制剂治疗神经胶质瘤
JP2005264016A (ja) 2004-03-19 2005-09-29 Fuji Photo Film Co Ltd インクジェット記録用インク、インクセット及びインクジェット記録方法
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
GB0412526D0 (en) 2004-06-05 2004-07-14 Leuven K U Res & Dev Type 2 diabetes
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7820654B2 (en) 2004-09-23 2010-10-26 Dr. Reddy's Laboratories Ltd. Pyrimidine compounds, process for their preparation and compositions containing them
WO2006038594A1 (fr) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Inhibiteur de canal de calcium de type n
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
AU2006208834A1 (en) 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
WO2006110761A2 (fr) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Forme de variante d'oxydase d'urate et utilisation associee
CA2611728A1 (fr) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methode d'identification, d'evaluation et de traitement de patients suivant un traitement anticancereux
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
AU2006283846B2 (en) 2005-08-26 2012-04-05 Merck Serono Sa Pyrazine derivatives and use as PI3K inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20100297673A1 (en) 2006-09-20 2010-11-25 Reddy Us Therapeutics Methods and compositions for upregulation of peroxiredoxin activity
US20080109846A1 (en) 2006-10-23 2008-05-08 Ewertz C Christian System and method for audiovisual content playback
JP2010508300A (ja) 2006-10-26 2010-03-18 フライン、ギャリー・エー． アクアポリン修飾因子並びに浮腫および体液平衡異常の治療のためのそれらの使用方法
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101679371A (zh) 2006-12-04 2010-03-24 艾美罗股份公司 作为腺苷受体拮抗剂的取代的嘧啶
CN105193799A (zh) 2006-12-08 2015-12-30 米伦纽姆医药公司 使用经口因子xa抑制剂治疗血栓形成的单位剂量调配物和方法
WO2008076883A2 (fr) 2006-12-15 2008-06-26 Abraxis Bioscience, Inc. Dérivés de triazine et leurs applications thérapeutiques
JP5450381B2 (ja) 2007-04-30 2014-03-26 プロメティック・バイオサイエンスィズ・インコーポレーテッド 化合物、そのような化合物を含有する組成物、及びそのような化合物を用いるがん及び自己免疫疾患の治療法
AU2008262291A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
PH12013501594A1 (en) 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
KR20100038108A (ko) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
TW200906818A (en) 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
TW200924778A (en) 2007-10-10 2009-06-16 Takeda Pharmaceutical Amide compound
CA2709784A1 (fr) 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
EP3782612B1 (fr) 2008-05-15 2023-11-08 Celgene Corporation Formulations orales d'analogues de cytidine et leurs procédés d'utilisation
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
WO2010028179A1 (fr) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Composés hétérocycliques comme modulateurs de gata
MX2011002409A (es) 2008-09-03 2011-09-06 Univ Johns Hopkins Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
EP2370417A2 (fr) 2008-11-21 2011-10-05 Millennium Pharmaceuticals, Inc. Sel de lactate du (4-isopropoxyphényl)-amide de l acide 4-(6-méthoxy-7-(3-pipéridin-1-yl-propoxy)quinazolin-4-yl¨pipérazine-1-carboxylique et les compositions pharmaceutiques l incluant dans le traitement du cancer et d'autres pathologies ou troubles
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP5263304B2 (ja) 2009-02-06 2013-08-14 日本新薬株式会社 アミノピラジン誘導体及び医薬
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
WO2010129596A1 (fr) 2009-05-04 2010-11-11 Agios Pharmaceuticals, Inc. Inhibiteurs de la pkm2 destinés à être utilisés dans le traitement du cancer
WO2010130638A1 (fr) 2009-05-14 2010-11-18 Evotec Ag Composés sulfamides, compositions pharmaceutiques et leurs utilisations
KR101460095B1 (ko) 2009-06-08 2014-11-10 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
CN102573487A (zh) 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 Hedgehog信号传导的吡啶基-三嗪抑制剂
AU2010258825B2 (en) 2009-06-09 2014-08-21 Nantbio, Inc. Ureidophenyl substituted triazine derivatives and their therapeutical applications
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
WO2011005209A1 (fr) 2009-07-10 2011-01-13 Milux Holding S.A. Prothèse du genou et méthode associée
CA2772194A1 (fr) 2009-09-01 2011-03-10 Pfizer Inc. Derives de benzimidazole
CA2773561A1 (fr) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie a la pleckstrine et leurs methodes d'utilisation
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
EP3561077B1 (fr) 2009-10-21 2022-12-21 Les Laboratoires Servier Procédés pour des troubles liés à la prolifération cellulaire
EP2491030B1 (fr) 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Analogues à cycles condensés d'agents anti-fibrotiques
JP5967827B2 (ja) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
NZ578968A (en) 2010-02-10 2011-03-31 Allans Sheetmetal And Engineering Services Fuel feed system for a pellet fire
WO2011123618A1 (fr) 2010-04-01 2011-10-06 Agios Pharmaceuticals, Inc. Procédés d'identification d'un composé candidat
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (fr) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Genès, enzymes et flux constituant des cibles métaboliques pour la thérapie contre le cancer
ES2704862T3 (es) 2010-07-16 2019-03-20 Agios Pharmaceuticals Inc Composiciones terapéuticamente activas y su método de uso
NZ609490A (en) 2010-10-21 2015-06-26 Biomarin Pharm Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012078288A2 (fr) * 2010-11-08 2012-06-14 Washington University Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë
AU2011336764B2 (en) 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012173682A2 (fr) 2011-03-29 2012-12-20 The Broad Institute, Inc. Composés et méthodes de traitement de maladies liées à l'isocitrate déshydrogénase
ES2746558T3 (es) 2011-05-03 2020-03-06 Agios Pharmaceuticals Inc Activadores de piruvato cinasa R para uso en terapia
SG194697A1 (en) * 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CA2834610A1 (fr) 2011-06-06 2012-12-13 Merck Sharp & Dohme Corp. Inhibition mediee par interference par arn de l'expression du gene de l'isocitrate deshydrogenase (idh1)
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
JP6116554B2 (ja) 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんの処置のための置換されたアザ複素環
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
US9167820B2 (en) 2011-07-22 2015-10-27 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
EP2804850B1 (fr) 2012-01-19 2018-08-29 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2634259A1 (fr) 2012-03-01 2013-09-04 Deutsches Krebsforschungszentrum Supports et procédés pour la détermination du (D)-2-hydroxyglutarate (D2HG)
WO2013133367A1 (fr) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 Nouveau dérivé de triazine
JP2015512630A (ja) 2012-03-12 2015-04-30 メモリアル スローン−ケタリング キャンサー センター 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物
WO2014015422A1 (fr) 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Nanoparticules à base de cellulose pour administration de médicament
WO2014062511A1 (fr) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127173A1 (fr) 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Composés thérapeutiquement actifs et leurs procédés d'utilisation
WO2015127172A1 (fr) 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs procédés d'utilisation
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
BR122023021436A2 (pt) 2014-03-14 2023-12-12 Les Laboratoires Servier Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
SG11201803088PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
US10111882B2 (en) 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors

Also Published As

Publication number Publication date
AU2016338552B2 (en) 2022-04-28
IL258684A (en) 2018-06-28
JP2018534286A (ja) 2018-11-22
DK3362065T3 (da) 2024-06-17
BR112018007671A2 (pt) 2018-11-06
JP2021119152A (ja) 2021-08-12
SMT202400238T1 (it) 2024-07-09
IL258684B (en) 2022-12-01
ZA201803162B (en) 2023-12-20
IL258684B2 (en) 2023-04-01
CA3216701A1 (fr) 2017-04-20
AU2016338552A1 (en) 2018-05-31
ES2981538T3 (es) 2024-10-09
HUE067449T2 (hu) 2024-10-28
SG11201803088PA (en) 2018-05-30
EP3362065B1 (fr) 2024-04-03
MA71411A (fr) 2025-04-30
FI3362065T3 (fi) 2024-06-19
UA123401C2 (uk) 2021-03-31
WO2017066566A1 (fr) 2017-04-20
PL3362065T3 (pl) 2024-09-16
MX390531B (es) 2025-03-20
MD3362065T2 (ro) 2024-08-31
RS65668B1 (sr) 2024-07-31
MA42999A (fr) 2018-08-22
US20180303808A1 (en) 2018-10-25
KR20250126877A (ko) 2025-08-25
KR20180061372A (ko) 2018-06-07
SI3362065T1 (sl) 2024-08-30
CN121513029A (zh) 2026-02-13
JP6871920B2 (ja) 2021-05-19
US11419859B2 (en) 2022-08-23
SG10202111439SA (en) 2021-11-29
PT3362065T (pt) 2024-06-21
EP3362065A1 (fr) 2018-08-22
BR112018007671B1 (pt) 2023-10-17
LT3362065T (lt) 2024-07-25
EP3362065A4 (fr) 2019-06-19
CA3002067C (fr) 2023-11-28
EP4403173A2 (fr) 2024-07-24
CN108472291A (zh) 2018-08-31
HRP20240817T1 (hr) 2024-09-27
MX2018004587A (es) 2018-08-14
EP4403173A3 (fr) 2024-10-09
CA3002067A1 (fr) 2017-04-20

Similar Documents

Publication Publication Date Title
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MA41013B1 (fr) Compositions comprenant des souches bactériennes
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
EA201991455A1 (ru) Композиции и способы лечения дефицита альфа-1-антитрипсина
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
TW200716141A (en) Compositions and methods for treatment for neoplasms
PH12022551105A1 (en) Tyk2 pseudokinase ligands
FR3107648B1 (fr) conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
BR112019008374A2 (pt) inibidor seletivo de egfr mutante por inserção do éxon 20
MA39885A (fr) Procédés de caractérisation et de traitement de la leucémie myéloïde aiguë
MA48939B1 (fr) Compositions comprenant des souches bactériennes
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
EA202192047A1 (ru) Соединения и их применение